Hetero launches its generic semaglutide portfolio in international markets, enhancing access to advanced diabetes and obesity therapies.
Hetero has launched its generic semaglutide portfolio in overseas markets even as it is awaiting regulatory approvals in India.
The launch represents the beginning of a strategic, multi-year global rollout across more than 75 countries, as part of Hetero’s focus on improving access to advanced cardio-metabolic therapies.
Initial launches are underway in Africa, Asia and West Asia, with further rollouts planned, subject to regulatory approvals.
The injectable semaglutide therapies will be marketed under the brand names Truglyx, Rolmodl and Moto G across markets.
Clinical trials
Hetero is currently awaiting approval from India’s national regulator, CDSCO, following the completion of clinical trials in type 2 diabetes and obesity.
Launch in India is anticipated post regulatory approvals.
“We have developed a single, global-quality product platform, reflecting our capabilities in advanced product development and the manufacturing of complex generics. Leveraging our established commercial networks across Asia, West Asia, Africa and Latin America, we remain focused on expanding access to high-quality therapies in the diabetes and metabolic care space, while ensuring a consistent global supply,’’ Vamsi Krishna Bandi, Managing Director, Hetero said on Friday.
The portfolio will be available in multi-dose disposable pen devices designed in line with innovator formats, and across multiple dose strengths including 0.25 mg, 0.5 mg, 1 mg, 2 mg, 1.7 mg and 2.4 mg, supporting both type 2 diabetes and weight management, and enabling flexible, patient-centric dosing, it added.
Source : thehindubusinessline
